Terminated PHASE1 INTERVENTIONAL 2-arm NCT00509756

Study Evaluating FXR-450 in Healthy Japanese Men

Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of FXR-450 Administered Orally to Healthy Japanese Male Subjects

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Conditions Healthy

Interventions FXR-450 Placebo

Updated 5 times since 2017 Last updated: Oct 21, 2010 Started: Nov 30, 2007 Primary completion: Feb 29, 2008 Completion: Feb 29, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Please see termination statement in the detailed description.

Other terminated trials from Wyeth is now a wholly owned subsidiary of Pfizer

See all terminations from Wyeth is now a wholly owned subsidiary of Pfizer

Other Healthy trials with similar outcome

Browse all Healthy trials

Listed as NCT00509756, this PHASE1 trial focuses on Healthy and remains terminated or withdrawn. Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, it has been updated 5 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE1

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Wyeth is now a wholly owned subsidiary of Pfizer

Data source: Wyeth is now a wholly owned subsidiary of Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tokyo, Japan